- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06293469
Cobertura acelerada de retalho em trauma grave de extremidade inferior (FLAP ATTACK)
Cobertura acelerada do retalho versus tempo padrão no tratamento de lesões musculoesqueléticas graves das extremidades inferiores
The goal of this randomized controlled trial is to determine if accelerated flap coverage compared to standard flap coverage timing leads to improved infection-related complications in patients with open fractures and/or dislocations below the knee. Eligible patients will be randomized to receive either a flap within a goal of 72 hours of injury or standard of care flap timing for the institution. The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility).
This is the vanguard and international part of the FLAP ATTACK trial.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Infection following severe lower extremity musculoskeletal injuries is a challenging problem. Several factors hypothesized to influence infection have been explored and, in many cases, optimized or found not to be influential. A persistent area of uncertainty and variability is the timing of acute soft tissue coverage. In the United States, the mean time to coverage from injury is 10 days, and infection rates are 20-35%. In the United Kingdom, there are national guidelines to support coverage within 72 hours of injury, and infection rates are less than 10%. While the data to support early coverage is promising, the necessary evidence to make this significant change is lacking. To justify the mobilization of resources and expense required to shift practice, a definitive trial is needed. This trial seeks to fill this critical knowledge gap.
The primary objective of this trial is to determine if accelerated flap coverage (within 72 hours of injury) compared to standard flap coverage timing leads lower rates of infection and infection-related complications. The trial population includes patients 18 years and older with an acute open fracture and/or dislocation below the knee, with a diagnosed need for acute soft tissue coverage with a flap. Patients who undergo primary amputation prior to attempted flap coverage will be excluded. There will be 356 participants randomized in 1:1 ratio to receive either accelerated flap coverage (goal of flap within 72 hours from injury) or flap coverage at the time that reflects the standard of care at each institution. The timing of the trial interventions, other adjunctive treatments, the fracture fixation, and flap coverage procedures will be documented for both treatment groups. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. Participants will have follow-up at 6 weeks, 3 months, 6 months, and 12 months post-randomization.
The primary outcome will be a composite outcome to evaluate clinical status 6 months after randomization. Components of the composite outcome will be hierarchically assessed in the following order: 1) all-cause mortality, 2) amputation related to injury, 3) re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure), and 4) days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility). The secondary outcomes will independently assess the individual components of the primary outcome at 6 and 12 months, the composite outcome at 12 months, and health-related quality of life and patient satisfaction over 6 and 12 months. An Adjudication Committee will review primary and secondary endpoints and a Data Safety Monitoring Committee (DSMC) will review all safety events.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Lily Mundy, MD
- Número de telefone: 410-706-2492
- E-mail: LMundy3@jhu.edu
Locais de estudo
-
-
Victoria
-
Melbourne, Victoria, Austrália, 3004
- Recrutamento
- The Alfred Hospital
-
Contato:
- Lipi Shukla, MBBS, PhD
-
Investigador principal:
- Lipi Shukla, MBBS, PhD
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 1N1
- Recrutamento
- Vancouver General Hospital
-
Contato:
- David Stockton, MD
- Número de telefone: 604-875-4111
- E-mail: david.stockton@vch.ca
-
-
New Brunswick
-
Saint John, New Brunswick, Canadá, E2L 4L2
- Recrutamento
- Saint John Regional Hospital
-
Contato:
- Alison Wong, MD
- Número de telefone: 506-648-6000
- E-mail: alison.wong@dal.ca
-
-
Ontario
-
Toronto, Ontario, Canadá, M4N 3M5
- Recrutamento
- Sunnybrook Health Sciences Centre
-
Contato:
- Jana Dengler
- Número de telefone: 416-480-6100
- E-mail: jana.dengler@sunnybrook.ca
-
-
-
-
-
Barcelona, Espanha, 08035
- Recrutamento
- Vall d'Hebron University Hospital
-
Contato:
- Jordi Tomás-Hernández, MD
-
Investigador principal:
- Antonio Bulla, MD, PhD
-
Investigador principal:
- Jordi Tomás-Hernández, MD
-
-
-
-
California
-
Sacramento, California, Estados Unidos, 95817
- Recrutamento
- UC Davis Medical Center
-
Contato:
- Ara A Salibian, MD
-
Investigador principal:
- Ara A Salibian, MD
-
Investigador principal:
- Augustine M Saiz, MD
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Recrutamento
- The Johns Hopkins Hospital
-
Contato:
- Lily R Mundy, MD
-
Investigador principal:
- Lily R Mundy, MD
-
Baltimore, Maryland, Estados Unidos, 21224
- Recrutamento
- John Hopkins Bayview Medical Center
-
Contato:
- Lily R Mundy, MD
-
Investigador principal:
- Lily R Mundy, MD
-
Baltimore, Maryland, Estados Unidos, 21201
- Recrutamento
- R Adams Cowley Shock Trauma Center
-
Contato:
- Mark J Gage, MD
-
Investigador principal:
- Mark J Gage, MD
-
Largo, Maryland, Estados Unidos, 20774
- Recrutamento
- University of Maryland Capital Region Medical Center
-
Contato:
- Todd Jaeblon, MD
-
Investigador principal:
- Todd Jaeblon, MD
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Recrutamento
- Oregon Health & Science University
-
Contato:
- Graham J DeKeyser, MD
-
Investigador principal:
- Graham J DeKeyser, MD
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Recrutamento
- Vanderbilt University Medical Center
-
Contato:
- Lauren M Tatman, MD
-
Investigador principal:
- Lauren M Tatman, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
The inclusion criteria are:
- Patients 18 years of age or older.
- Severe lower extremity open fracture and/or dislocation below the knee requiring an acute flap for management of the musculoskeletal injury.
- Will have all planned flap surgeries performed by a participating surgeon or delegate.
- Able to be randomized within 48 hours of injury.
The exclusion criteria are:
- Site is unable to implement the accelerated flap protocol due to local logistics.
- Primary amputation anticipated prior to attempted flap for management of the injury.
- Critical limb ischemia that requires re-vascularization for limb perfusion.
- Chronic or acute infection at or near the musculoskeletal injury site at the time of initial injury surgery.
- Burns at the musculoskeletal injury site.
- Incarceration.
- Expected injury survival of less than 12 months.
- Terminal illness with expected survival of less than 12 months.
- Currently enrolled in a trial that does not permit co-enrollment.
- Declined to provide informed consent.
- Unable to obtain informed consent due to language barriers.
- Unable to obtain informed consent because a legally authorized representative was unavailable.
- Anticipated problems, in the judgment of research personnel, with maintaining follow-up with the patient.
- Prior enrollment in the trial.
- Eligible patient or LAR was not approached within screening window (missed participant).
- Other reason to exclude the patient, as approved by the Principal Investigators.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Accelerated Flap Coverage
Accelerated flap surgery timing at a goal of within 72 hours from injury. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. |
Timing of the flap surgery is with a goal of 72 hours from injury |
|
Comparador Ativo: Standard of Care Flap Timing
The flap surgery will be performed at the standard of care timing for the institution. Management of the fracture or dislocation, selection of flap, and post-injury flap management will be at the discretion of the operating surgeons and documented for both treatment groups. |
Timing of the flap surgery is the standard of care flap timing for the participating institution. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Clinical status
Prazo: 6 months
|
Clinical status is a hierarchical composite of the following outcomes:
|
6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mortality
Prazo: 6 months and 12 months
|
All-cause mortality. Mortality will be time-to-event, with the assumption that earlier is worse than later. |
6 months and 12 months
|
|
Amputation
Prazo: 6 months and 12 months
|
Amputation related to injury. Amputation will be time-to-event, with the assumption that earlier is worse than later. |
6 months and 12 months
|
|
Unplanned re-operation
Prazo: 6 months and 12 months
|
Unplanned re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure). Re-operation for infection and major flap complication will account for more than one operation, assuming that more operations are worse. |
6 months and 12 months
|
|
Number of days in hospital
Prazo: 6 months and 12 months
|
Days in an acute in-patient hospital (i.e., not rehab or nursing facility) |
6 months and 12 months
|
|
Patient-reported health status as assessed by the Euro-QoL (EQ-5D-5L)
Prazo: 6 months and 12 months
|
Patient-reported health status as assessed by the EQ-5D-5L. The EQ-5D-5L is scored on a 0 to 100 mm scale. 0 mm represents "the worst health you can imagine to 100 mm which represents "the best health you can imagine". |
6 months and 12 months
|
|
Quality of life as assessed by the Limb-Q
Prazo: 6 months and 12 months
|
Health-related quality of life and patient satisfaction measured with the Limb-Q. The Limb-Q is a set of independently functioning scales. All scales are scored 0-100 (higher = better). The Limb-Q Appearance, Physical, Symptoms, Financial Impact, Life Impact, and Psychological scales will be used. |
6 months and 12 months
|
|
Clinical Status
Prazo: 12 months
|
Clinical status is a hierarchical composite of the following outcomes: 1. All-cause mortality 2. Amputation related to injury 3. Re-operation for infection and/or flap complication (flap compromise, partial and/or complete flap failure) 4. Days in hospital, defined as days in an acute in-patient hospital (i.e., not rehab or nursing facility) |
12 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Lily Mundy, MD, Johns Hopkins School of Medicine
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- IRB00434587
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .